Taven

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Taven

Property Description
Active Ingredient Atorvastatin
Form Film-coated tablets
Pharmacological Class Statin (HMG-CoA Reductase Inhibitor)
Common Use Managing elevated blood cholesterol (Dyslipidemia)
Origin Synthetic drug

Taven is a prescription medicine utilized as an antihyperlipidemic agent for the management of high cholesterol and related conditions. It is a synthetic, single-ingredient pharmaceutical preparation that works by targeting the body's internal lipid production. This positions Taven as a foundational cardiovascular therapy that addresses the underlying issues of elevated lipids in the blood.


Taven Composition and Classification

The active substance in Taven is Atorvastatin, supplied as Atorvastatin calcium. This molecule gives the drug its definitive classification as a statin, belonging to the HMG-CoA reductase inhibitor class. This classification is clinically recognized for its mechanism in reducing the rate of cholesterol biosynthesis in the liver.

As a single-ingredient product, Taven is formulated as a film-coated tablet intended for oral administration, ensuring a standardized and reliable delivery of the active compound, Atorvastatin, which is a chemically synthesized drug.


General Purpose and Core Benefit

The primary purpose of Taven is to achieve the reduction of elevated cholesterol levels circulating in the blood. This targeted action directly addresses conditions such as hypercholesterolemia and dyslipidemia.

A review of statins confirms their key therapeutic role in improving lipid profiles: Atorvastatin is used to lower "bad cholesterol" (LDL) and fats (triglycerides), and raise "good cholesterol" (HDL) in the blood. The overall therapeutic goal is to modulate the patient’s lipid profile toward established healthy targets, serving as a powerful systemic tool for managing a major cardiovascular risk factor in adult patient groups.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Taven?

Possible Side Effects and Safety Information

The safety profile for Taven (Atorvastatin) is formally classified based on the frequency of events observed in clinical studies, covering various System-Organ Classes (SOCs). Reactions listed as Common (occurring in 1% to 10% of patients) often involve the nervous system (e.g., headache), the gastrointestinal system (e.g., diarrhea, flatulence, nausea), and the musculoskeletal system (e.g., myalgia, arthralgia, or joint pain). Abnormalities in blood tests, such as elevated liver function enzymes and increased blood creatine kinase (CK) levels, are also commonly reported in official regulatory documents.


Serious Adverse Reactions and Safety Constraints

The regulatory label documents specific, rare, but clinically significant events. These include Myopathy (muscle disease) and the more severe Rhabdomyolysis, a condition of severe muscle breakdown that can lead to acute kidney injury. Rare reports of Hepatic Failure and severe allergic reactions such as Anaphylaxis have also been officially noted.


Population-Specific Safety and Exposure Patterns

Specific safety constraints are stated for certain populations: Taven is formally Contraindicated for use in women who are pregnant or breast-feeding, and in individuals with active liver disease. Safety notes also indicate that the risk of certain adverse reactions, such as those affecting the muscle or liver, may be increased when taken concomitantly with certain other medications. Furthermore, some reactions may be observed more frequently at the initiation of treatment or during a dose escalation phase.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Taven (Levofloxacin) overdose focuses on managing specific, serious toxicities documented in prescribing information. Acute overdosage may result in two primary types of severe documented manifestations.

Documented Overdose Manifestations

System Affected Manifestations Listed in Labeling
Central Nervous System (CNS) Confusion, dizziness, impairment of consciousness, and convulsive seizures.
Cardiovascular System Prolongation of the QT interval, carrying a serious risk of life-threatening ventricular arrhythmias, such as Torsades de pointes.

Immediate Actions Required

In the event of an acute overdosage, immediate medical attention must be sought. Official regulatory documents state that there is no specific antidote for Levofloxacin. The acute management is supportive and symptomatic, and includes maintaining appropriate hydration and observation of the patient.

Due to the significant risk to the heart, mandatory ECG monitoring is required to monitor for QT interval changes. Gastric lavage may also be considered in acute settings to empty the stomach. The drug is not efficiently removed by standard hemodialysis or peritoneal dialysis.

Therapeutic Uses of Taven

What Taven Treats: Main Uses and Benefits


Taven is commonly used to help manage the systemic imbalance of dyslipidemia, which involves abnormal levels of lipids in the blood, including hypercholesterolemia (high cholesterol). The core therapeutic benefit is commonly used to help with the management of these levels, contributing to the management of symptoms related to systemic imbalance, such as high LDL-C and triglycerides, and supporting HDL-C. This long-term action is considered relevant for easing the overall burden of chronic systemic risk. Its application includes the management of high cholesterol, primary hyperlipidemia, and managing the risk of heart attack and stroke.

Key Therapeutic Contexts

Taven may play a role in managing the risk associated with conditions marked by increased physiological stress, where supportive management is appropriate. Its use is considered relevant for easing the overall symptom load for both primary prevention (reducing a first event risk) and secondary prevention (managing recurrence risk in established disease). The medication is applied in addressing conditions presenting with systemic or localized discomfort in high-risk populations, including adult patients with Type 2 Diabetes Mellitus and adolescents aged 10 and older to manage Familial Hypercholesterolemia.

Quick Fact: Relief for Silent Cardiovascular Risk

Taven may assist with maintaining functional stability by addressing symptoms related to systemic imbalance over time.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Taven’s eligibility is strictly defined by regulatory authorities based on age, physiological state, and existing health conditions. The official prescribing information establishes clear rules for who may use the medicine and who is absolutely excluded.


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults (18 years and older); Pediatric patients aged 10 years and older (for specific high cholesterol types).
Populations for whom use is contraindicated Patients with Active Liver Disease (including unexplained, persistent transaminase elevations); Patients with known Hypersensitivity to the drug; Patients who are Pregnant; Patients who are Breastfeeding or women of childbearing potential not using adequate contraception.
Age-related eligibility rules Use is not established or not indicated in children younger than 10 years. Advanced age (ge 65) is recognized as a factor increasing the risk of muscle disorders.
Eligibility-related restrictions Use requires caution in patients with pre-disposing factors for serious muscle damage (myopathy), such as severe renal impairment or uncontrolled hypothyroidism.

Eligibility Classifications (High-Level)

The official prescribing information classifies use in certain groups as Contraindicated (e.g., in active liver disease) and mandates Use with Caution for others (e.g., those with risk factors for myopathy).

Resulting Eligibility Structure

Official eligibility statements:

  • Taven is contraindicated in patients with active liver disease or hypersensitivity to its components.
  • Use is strictly contraindicated during pregnancy and lactation.
  • Eligibility for pediatric patients is limited to those 10 years of age and older.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Taven by establishing Absolute Contraindications based on hepatic function and physiological states (pregnancy/lactation) that necessitate complete exclusion from treatment. The profile sets age minimums and requires conditional caution for populations presenting with specific risk factors, such as advanced age or renal impairment.

What should I know about interactions with other medicines?

The official regulatory profile for Taven (Atorvastatin) establishes specific constraints for co-administration with other medicines and products.


Prohibited and High-Risk Combinations

Regulators advise against or formally contraindicate co-administration with specific medications, including Cyclosporine and the Hepatitis C combination Glecaprevir/Pibrentasvir. Co-administration with certain anti-HIV regimens, such as Tipranavir plus Ritonavir, is also cautioned against due to the risk of severe exposure increase and potential for myopathy.

Pharmacokinetic and Exposure Effects

Atorvastatin is primarily metabolized by the CYP3A4 enzyme and is a substrate for OATP1B1 uptake transporters. Strong inhibitors of CYP3A4 (e.g., Clarithromycin, Itraconazole) and OATP inhibitors significantly increase atorvastatin plasma concentrations. Conversely, CYP3A4 inducers, such as Rifampin, may reduce its plasma levels. Atorvastatin also causes an officially documented increase in the plasma levels of Oral Contraceptives containing norethindrone and ethinyl estradiol.

Pharmacodynamic and Timing Rules

The risk of muscle-related effects is officially enhanced when co-administered with Fibric Acid Derivatives (like Gemfibrozil) and high-dose Niacin (ge 1 g/day). A separate timing requirement exists for Rifampin, which must be co-administered simultaneously to maintain Taven's efficacy. Consuming large quantities of grapefruit juice (ge 1.2 liters/day) is not recommended as it increases systemic exposure. Chronic alcoholic liver disease is noted as a population condition where atorvastatin plasma concentrations are markedly increased.

Mechanism of Action

Key Mechanism: Enzyme Inhibition and Enhanced Hepatic Clearance

The primary action involves selective, competitive inhibition of the HMG-CoA reductase enzyme, which governs the rate-limiting step of cholesterol synthesis within liver cells. This molecular blockade triggers a cellular response that significantly increases the expression of LDL receptors on the hepatocyte surface. The resulting physiological effect is the rapid and highly efficient clearance of Low-Density Lipoprotein Cholesterol (LDL-C) and VLDL from the bloodstream, resulting in the systemic reduction of circulating LDL-C and VLDL.


Mechanism: Modulation of Vascular and Inflammatory Signaling

A secondary, non-lipid-driven effect is initiated by the drug's impact on the isoprenoid synthesis pathway, which is a byproduct of HMG-CoA reductase inhibition. This pathway influences the activation of regulatory proteins (GTP-binding proteins) essential for blood vessel function and cellular signaling. The mechanism results in enhanced endothelial-dependent vasorelaxation and involves the modulation of matrix metalloproteinase activity, leading to systemic modulation of inflammatory mediators (e.g., C-reactive protein).

Dosage and Administration Information

Taven (atorvastatin) is formulated as film-coated tablets intended for oral administration. The general principle of its use involves a standardized, once-daily dosing regimen, and the tablets may be taken at any time of the day, with or without food. This flexibility supports adherence to the long-term administration course.

For adults, the typical starting dose is 10 mg or 20 mg once daily, although an initial dose of 40 mg may be utilized for patients requiring a substantial reduction in low-density lipoprotein cholesterol. The maximum recommended dose in the adult population is 80 mg once daily. The official usage protocol dictates that any dose adjustment, or titration, should occur at minimum intervals of four weeks or more following the initiation of treatment to allow time for the effect to stabilize.

Usage in children aged 10 and older is generally initiated at a 10 mg dose once daily, with a maximum dose of 20 mg daily for Heterozygous Familial Hypercholesterolemia. Procedural guidance for a missed dose specifies that the missed dose should be skipped entirely, and the patient must resume the next regularly scheduled dose; double dosing is prohibited. Furthermore, the maximum daily dose must be reduced when co-administered with specific medications (e.g., cyclosporine, clarithromycin), and concurrent intake of large quantities of grapefruit juice is generally restricted due to administration constraints. This structured approach defines the usage protocol for Taven.

Recent Clinical Evidence

Taven: Recent Clinical Evidence

Clinical research has focused on the preventative use of Taven (Atogepant) for both episodic and chronic migraine. The available evidence, primarily derived from Phase III, randomized, placebo-controlled trials, centers on measured changes in monthly headache metrics.


Evidence in Migraine Prevention

Studies have included patient populations experiencing both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month).

  • Primary Outcome: A primary outcome examined in major trials was the change from baseline in the mean number of monthly migraine days (MMD). Reported reductions in MMD were observed in the treatment groups compared to placebo across both episodic and chronic migraine populations.
  • Secondary Outcomes: Secondary measures included measured changes in patient-reported quality of life scores and the exploration of differences between study groups in measured pain intensity scores.

Trials reported that differences in headache frequency between the treatment group and placebo group were typically assessed at the 12-week endpoint.


Safety and Trial Population

The overall safety profile was evaluated across all main Phase II and Phase III trials. The initial safety profile was examined in studies utilizing a defined dosage regimen. The trials included specific patient populations who met defined criteria regarding prior acute treatment history.

Patients with pre-existing heart conditions were generally excluded from the primary trials. Investigators continue to collect additional safety data in this specific population. Evidence remains limited regarding the long-term safety of Taven beyond one year of continuous use; ongoing research continues to monitor these effects.

Key Studies & References

  1. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

Frequently Asked Questions (FAQ)

Common questions about Taven (FAQ)

Q: Is Taven the same type of medicine as [similar competing drug name]?

A: According to the official product information, Taven belongs to the class of medicines known as statins, or HMG-CoA reductase inhibitors. These medicines work by reducing the rate of cholesterol synthesis in the liver. This classification defines the way the medicine works compared to other treatments.


Q: Is Taven safe to take for a long time?

A: Taven is a medication intended for long-term use in managing chronic conditions like high cholesterol and reducing the risk of cardiovascular events. Its safety profile is established through clinical studies for its approved indications. Its continued use is determined by a healthcare professional based on the individual's long-term treatment goals.


Q: What kind of studies have been done on Taven?

A: Clinical studies have included large-scale, controlled trials investigating Taven’s effect on reducing LDL-C (sometimes called 'bad cholesterol'), total cholesterol, and the risk of cardiovascular events. Official information focuses on its efficacy and safety in various patient populations for its primary uses.


Q: Can men and women use Taven for the same condition?

A: Taven is indicated for use in both men and women to treat the same cholesterol conditions. However, the official label states it is strictly contraindicated for use in women who are pregnant, may become pregnant, or are breastfeeding.


Q: Are there known issues with Taven and alcohol consumption?

A: Taven should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. This is because excessive alcohol intake or existing liver problems can increase the risk of certain side effects, as noted in official regulatory documents.


Q: Does Taven come in different strengths or forms?

A: Taven is available as film-coated tablets in several dosage strengths, which include 10 mg, 20 mg, 40 mg, and 80 mg. The available strengths allow a prescriber to select the appropriate dose for an individual’s treatment plan.


Q: What is the typical time frame for seeing the full effect of Taven?

A: The therapeutic response, specifically the reduction in LDL cholesterol levels, can be assessed as early as 4 weeks after starting treatment, as this is the minimum period before a dosage adjustment may be considered. Maximum effects on cholesterol levels are generally observed after several weeks of continuous therapy.


Q: Why is Taven sometimes prescribed instead of other treatments?

A: Taven is prescribed as a foundational cardiovascular therapy because it is highly effective at lowering LDL-C, VLDL-C, and triglycerides. Its approved indications confirm its role in reducing the risk of major cardiovascular events like heart attack and stroke in specific at-risk patients.


Q: How quickly does Taven usually start working?

A: Pharmacokinetic studies indicate that Taven is rapidly absorbed after oral administration. Maximum concentrations of the drug in the bloodstream typically occur within 1 to 2 hours of taking a dose.


Q: Does Taven cause weight gain or weight loss?

A: In the official regulatory documents, weight gain is listed as an uncommon adverse reaction associated with Taven. Weight loss, however, is not listed as a reported side effect.


Q: Can Taven be taken with common over-the-counter pain relievers?

A: The official regulatory information lists specific drug classes, such as strong CYP3A4 inhibitors, that can significantly interact with Taven. There are no general warnings for common over-the-counter pain relievers, but all co-administered medications are typically reviewed by a healthcare professional.


Q: Is it normal to feel tired or dizzy when first starting Taven?

A: Common side effects noted in clinical trials include headache. Other effects such as dizziness, fatigue, and general malaise are also sometimes reported as uncommon side effects.


Q: Can Taven affect my ability to drive or operate machinery?

A: Taven is not expected to have a significant influence on the ability to drive or use machines. However, official information indicates that caution is necessary if side effects like dizziness occur.


Q: How long do I need to take Taven before stopping?

A: Taven is prescribed for the long-term control of cholesterol levels. The official label notes that stopping the medication typically results in a return of cholesterol levels to the pre-treatment baseline. Decisions regarding discontinuing the medication are made in consultation with a healthcare professional.


Q: What if I accidentally took too much Taven?

A: In the event of an overdose, official regulatory information states there is no specific treatment established. Management is symptomatic and supportive, and immediate contact with a poison control center or emergency services is typically recommended.


Q: Does Taven have any known interactions with supplements or vitamins?

A: Specific vitamins or supplements are not individually listed in the official documents for interaction warnings. However, caution is advised when taking products that may affect the liver's metabolism, such as those impacting the CYP3A4 enzyme.


Q: Does Taven affect sleep patterns?

A: Insomnia (difficulty sleeping) is listed in the official regulatory documents as an uncommon psychiatric disorder side effect. Any changes in sleep patterns may be discussed with a healthcare provider.


Q: What should I do if a side effect of Taven bothers me?

A: Contacting a healthcare professional is the appropriate action if any severe symptoms are experienced, such as unexplained muscle pain, weakness, or signs of liver problems (e.g., yellowing of the skin or eyes). For less severe but bothersome side effects, consultation with the prescriber is typically the recommended procedure.


Q: Is there a generic version of Taven available?

A: Yes, the active ingredient in Taven, which is atorvastatin, is widely available in a generic form. This is a common practice for medicines once patent exclusivity has expired.


Q: Are the effects of Taven permanent or do they stop when the medicine is stopped?

A: The LDL-C-lowering effect of Taven is not permanent. If the medication is stopped, cholesterol levels are expected to return to the pre-treatment baseline, according to official regulatory information.


Q: How does the body get rid of Taven?

A: Taven is primarily metabolized, or broken down, in the liver. It is then eliminated mainly through bile following hepatic and/or extrahepatic metabolism. Very little of the dose (less than 2%) is recovered in the urine.


Q: Are there any warnings about Taven and sun exposure?

A: There are no specific warnings regarding photosensitivity or sun exposure listed in the official regulatory documents for Taven. Sun exposure should be managed based on general health guidelines.


Q: Does Taven affect my mood or mental state?

A: The official regulatory label for statins notes rare post-marketing reports of cognitive impairment, such as memory loss or confusion. These effects are usually non-serious and are typically reversible if the medication is discontinued.


Q: What if Taven doesn't seem to be working for me?

A: The efficacy of Taven is assessed by monitoring LDL-C levels, usually starting as early as 4 weeks after treatment begins. If the desired cholesterol reduction is not achieved, dosage adjustments or consideration of alternative options may occur during the structured treatment protocol.


Q: Is there a risk of dependence or addiction with Taven?

A: Taven is not a controlled substance, and the official regulatory documents do not indicate any risk of dependence or addiction associated with its use.


Q: Is Taven a controlled substance?

A: No, Taven is not classified as a controlled substance by regulatory agencies. It is, however, a prescription-only medicine.


Q: Why is Taven only available by prescription?

A: Taven is a prescription-only medicine because it is intended for use under the supervision of a healthcare professional. This supervision is necessary to monitor the therapeutic response and to manage the risk of potentially serious side effects, such as myopathy or liver enzyme elevations.


Q: Can Taven be crushed or split in half?

A: Taven is manufactured as a film-coated tablet. The practice of crushing or splitting tablets is typically confirmed with a pharmacist or healthcare professional to ensure the correct dose is maintained and the tablet’s physical integrity is not compromised during use.


Q: Is it necessary to have follow-up testing while taking Taven?

A: Yes, regulatory documents indicate that follow-up monitoring is advised. Liver enzymes should be considered for testing before starting therapy and periodically thereafter. LDL-C levels should also be assessed to check the therapeutic response.


Q: Does Taven have a Black Box Warning?

A: No, the official regulatory label for Taven (atorvastatin) does not carry a Black Box Warning. This is the most stringent type of warning required by the FDA.


Q: What are the common reasons people stop taking Taven?

A: The most common reasons for discontinuing Taven in clinical trials were adverse reactions. These typically involved the musculoskeletal system (such as muscle pain) and the gastrointestinal system.

How should Taven be stored and disposed of?

How to Store and Dispose of Taven

Taven (Atorvastatin) tablets must be stored according to specific regulatory conditions to maintain product stability and integrity.

Storage Requirement Official Condition
Temperature Controlled Room Temperature: 20 C to 25 C (68 F to 77 F)
Protection Store in a closed container, away from moisture, direct light, and excessive heat. Do not freeze.
Child Safety Keep out of the sight and reach of children.

The product must not be used past its labeled expiration date. For disposal, unused or expired Taven should not be discarded in household trash or down the drain. Regulatory guidance advises asking a healthcare professional or pharmacist about returning the medicine through an approved drug take-back program or following local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Taven found in:

A-Z Index: